27 January 2025 - Apellis Pharmaceuticals announced today that the TGA has approved Syfovre (pegcetacoplan) for the every-other-month treatment of adult patients with geographic atrophy secondary to age-related macular degeneration with an intact fovea and when central vision is threatened by geographic atrophy lesion growth. 

Syfovre is the first and only approved treatment for geographic atrophy in Australia.

Read Apellis Pharmaceuticals press release